Cargando…
15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
The two primary mechanisms by which iodinated contrast media (CM) causes contrast-induced acute kidney injury (CIAKI) are the hemodynamic effect causing intrarenal vasoconstriction and the tubular toxic effect causing acute tubular necrosis. Inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PG...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832987/ https://www.ncbi.nlm.nih.gov/pubmed/33459127 http://dx.doi.org/10.1080/0886022X.2020.1870139 |
_version_ | 1783641961841819648 |
---|---|
author | Kim, Byeong Woo Kim, Hye Jung Kim, Sun-Hee Baik, Hyung Joo Kang, Mi Seon Kim, Dong-Hyun Markowitz, Sanford D. Kang, Sun Woo Bae, Ki Beom |
author_facet | Kim, Byeong Woo Kim, Hye Jung Kim, Sun-Hee Baik, Hyung Joo Kang, Mi Seon Kim, Dong-Hyun Markowitz, Sanford D. Kang, Sun Woo Bae, Ki Beom |
author_sort | Kim, Byeong Woo |
collection | PubMed |
description | The two primary mechanisms by which iodinated contrast media (CM) causes contrast-induced acute kidney injury (CIAKI) are the hemodynamic effect causing intrarenal vasoconstriction and the tubular toxic effect causing acute tubular necrosis. Inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which degrades prostaglandin E(2) (PGE2), promotes tissue repair and regeneration in many organs. PGE2 causes intrarenal arterial vasodilation. In this study, we investigated whether a 15-PGDH inhibitor can act as a candidate for blocking these two major mechanisms of CIAKI. We established a CIAKI mouse model by injecting a 10 gram of iodine per body weight (gI/kg) dose of iodixanol into each mouse tail vein. A 15-PGDH inhibitor (SW033291), PGE1, or PGE2 were administered to compare the renal functional parameters, histologic injury, vasoconstriction, and renal blood flow changes. In addition, human renal proximal tubular epithelial cells were cultured in a CM-treated medium. SW033291, PGE1, or PGE2 were added to compare any changes in cell viability and apoptosis rate. CIAKI mice that received SW033291 had lower serum levels of creatinine, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1 (p < 0.001); lower histologic injury score and TUNEL positive rates (p < 0.001); and higher medullary arteriolar area (p < 0.05) and renal blood flow (p < 0.001) than CM + vehicle group. In cell culture experiments, Adding SW033291 increased the viability rate (p < 0.05) and decreased the apoptosis rate of the tubular epithelial cells (p < 0.001). This 15-PGDH inhibitor blocks the two primary mechanisms of CIAKI, intrarenal vasoconstriction and tubular cell toxicity, and thus has the potential to be a novel prophylaxis for CIAKI. Abbreviations: 15-PGDH: 15-hydroxyprostaglandin dehydrogenase; AMP: adenosine monophosphate; CIAKI: contrast-induced acute kidney injury; CM: contrast media; EP: prostaglandin E2 receptor; hRPTECs: human-derived renal proximal tubule epithelial cells; KIM-1: kidney injury molecule-1; MTT: 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NGAL: neutrophil gelatinase-associated lipocalin; PBS: phosphate-buffered saline; PGE1: prostaglandin E(1); PGE2: prostaglandin E(2); RBF: renal blood flow; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; α-SMA: α-Smooth muscle actin |
format | Online Article Text |
id | pubmed-7832987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-78329872021-02-02 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury Kim, Byeong Woo Kim, Hye Jung Kim, Sun-Hee Baik, Hyung Joo Kang, Mi Seon Kim, Dong-Hyun Markowitz, Sanford D. Kang, Sun Woo Bae, Ki Beom Ren Fail Laboratory Study The two primary mechanisms by which iodinated contrast media (CM) causes contrast-induced acute kidney injury (CIAKI) are the hemodynamic effect causing intrarenal vasoconstriction and the tubular toxic effect causing acute tubular necrosis. Inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which degrades prostaglandin E(2) (PGE2), promotes tissue repair and regeneration in many organs. PGE2 causes intrarenal arterial vasodilation. In this study, we investigated whether a 15-PGDH inhibitor can act as a candidate for blocking these two major mechanisms of CIAKI. We established a CIAKI mouse model by injecting a 10 gram of iodine per body weight (gI/kg) dose of iodixanol into each mouse tail vein. A 15-PGDH inhibitor (SW033291), PGE1, or PGE2 were administered to compare the renal functional parameters, histologic injury, vasoconstriction, and renal blood flow changes. In addition, human renal proximal tubular epithelial cells were cultured in a CM-treated medium. SW033291, PGE1, or PGE2 were added to compare any changes in cell viability and apoptosis rate. CIAKI mice that received SW033291 had lower serum levels of creatinine, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1 (p < 0.001); lower histologic injury score and TUNEL positive rates (p < 0.001); and higher medullary arteriolar area (p < 0.05) and renal blood flow (p < 0.001) than CM + vehicle group. In cell culture experiments, Adding SW033291 increased the viability rate (p < 0.05) and decreased the apoptosis rate of the tubular epithelial cells (p < 0.001). This 15-PGDH inhibitor blocks the two primary mechanisms of CIAKI, intrarenal vasoconstriction and tubular cell toxicity, and thus has the potential to be a novel prophylaxis for CIAKI. Abbreviations: 15-PGDH: 15-hydroxyprostaglandin dehydrogenase; AMP: adenosine monophosphate; CIAKI: contrast-induced acute kidney injury; CM: contrast media; EP: prostaglandin E2 receptor; hRPTECs: human-derived renal proximal tubule epithelial cells; KIM-1: kidney injury molecule-1; MTT: 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NGAL: neutrophil gelatinase-associated lipocalin; PBS: phosphate-buffered saline; PGE1: prostaglandin E(1); PGE2: prostaglandin E(2); RBF: renal blood flow; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; α-SMA: α-Smooth muscle actin Taylor & Francis 2021-01-17 /pmc/articles/PMC7832987/ /pubmed/33459127 http://dx.doi.org/10.1080/0886022X.2020.1870139 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Laboratory Study Kim, Byeong Woo Kim, Hye Jung Kim, Sun-Hee Baik, Hyung Joo Kang, Mi Seon Kim, Dong-Hyun Markowitz, Sanford D. Kang, Sun Woo Bae, Ki Beom 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
title | 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
title_full | 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
title_fullStr | 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
title_full_unstemmed | 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
title_short | 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
title_sort | 15-hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury |
topic | Laboratory Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832987/ https://www.ncbi.nlm.nih.gov/pubmed/33459127 http://dx.doi.org/10.1080/0886022X.2020.1870139 |
work_keys_str_mv | AT kimbyeongwoo 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT kimhyejung 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT kimsunhee 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT baikhyungjoo 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT kangmiseon 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT kimdonghyun 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT markowitzsanfordd 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT kangsunwoo 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury AT baekibeom 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury |